Phase 1, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB080-00-AB (VRC01LS), Administered Intravenously or Subcutaneously to Healthy Adults

Trial Details:

I Ongoing
National Institute of Allergy and Infectious Diseases (NIAID) October 01, 2015
VRCHIVMAB080-00-AB VRC01-LS is the VRC01 mAb modified by site-directed mutagenesis to increase its binding affinity for FcRn.
VRCHIVMAB080-00-AB Passive Immunization
USA 40